Precision medicine

SQI Diagnostics Reports Second Quarter 2022 Results

Retrieved on: 
Thursday, May 26, 2022
Physician, Quality, Company, R, Informatics, Multimedia, SQI, Science, Patient, Lung, COVID19, COVID-19, ICU, TSX Venture Exchange, Engineering, UHN, Federal aid during the COVID-19 pandemic in Canada, New York State Department of Health, CLIA, Antibody, Precision medicine, Acquisition, NYSDOH, Growth, CEO, Medical device, Mobile phone, Pharmaceutical industry

TORONTO, May 26, 2022 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the first quarter for fiscal year ending September 30, 2022.

Key Points: 
  • TORONTO, May 26, 2022 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the first quarter for fiscal year ending September 30, 2022.
  • Sales were significantly greater than any quarter in SQI's history, coming in at $5.6M in Q2 2022, compared to $0.3M in Q2 2021.
  • Following the quarter, this credit facility was extended for another 2 months and is due on June 11, 2022.
  • SQI Diagnostics is driven to create and market life-saving testing technologies that help more people in more places live longer, healthier lives.

Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference

Retrieved on: 
Thursday, May 26, 2022
Physician, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Lipotriches exagens, Patient, Solution, COVID-19, Research, Medicare, SAN, Conference, Interest, Therapy, Precision medicine, Movement, Twitter, SEC, XGN, GLOBE, Laboratory, Security (finance), CA, Annual report, Rheumatology, Pharmaceutical industry

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth Stock Conference, which takes place June 6-9, 2022, in Chicago at the Loews Chicago Hotel.

Key Points: 
  • SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth Stock Conference, which takes place June 6-9, 2022, in Chicago at the Loews Chicago Hotel.
  • Interested parties may access the webcast of the presentation using a link on Exagens website at https://investors.exagen.com/events .
  • Exagen (Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions.
  • Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery

Retrieved on: 
Thursday, May 26, 2022
Longevity, RNA transfection, Company, Medicine, AI, Respiratory disease, Science, Patient, Health, D, Research, Whole genome sequencing, RNA, Genomics, Technology, Ovarian cancer, Therapy, Precision medicine, Immune system, Sirna, Diagnosis, COVID, CEO, GLOBE, Vaccine, Pharmaceutical industry, Antibiotics

Personalized medicine needs personalized data, and our progress in the last 18 months alone demonstrates the value of genomic data to research and discovery drug development, said Andrea Riposati, CEO of Dante Genomics.

Key Points: 
  • Personalized medicine needs personalized data, and our progress in the last 18 months alone demonstrates the value of genomic data to research and discovery drug development, said Andrea Riposati, CEO of Dante Genomics.
  • Dante has advanced its internal drug programs in muscle rare disease and neurological rare disease into the pre-clinical phase.
  • The Company also announced its rebrand to Dante Genomics to better reflect its global efforts in genomic information and personalized medicine.
  • Since its foundation, Dante Genomics has delivered hundreds of thousands of people with affordable, quality genomic solutions to inform their healthcare decisions.

Prometheus Biosciences to Participate at the Jefferies Healthcare Conference

Retrieved on: 
Thursday, May 26, 2022
UC, Company, TL1A, ATHENA, Patient, Event, CD, APOLLO, SAN, Conference, Ulcer, Ulcerative colitis, Precision medicine, Mab, Immunoglobulin G, GLOBE, Vaccine

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc .

Key Points: 
  • SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc .
  • (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will present at the Jefferies Healthcare Conference on June 8, 2022 at 10:00 AM ET.
  • A live and archived webcast of the presentation will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.
  • Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.

OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

Retrieved on: 
Thursday, May 26, 2022
Microbiology, Risk, Kantonsspital St. Gallen, Nasdaq, Infection, Teaching hospital, Patient, Bronchoalveolar lavage, Randomized controlled trial, Pneumonia, HPN, Flagship, Adult, Mortality, BAL, Culture, Gram, Safety, Bronchoscopy, Gram-negative bacteria, PCR, Precision medicine, GLOBE, Medicine, Pharmaceutical industry

The Unyvero results for Gram-negative bacteria were disclosed to the attending physician treating the patients in the intervention group approximately 5 hours after bronchoscopy.

Key Points: 
  • The Unyvero results for Gram-negative bacteria were disclosed to the attending physician treating the patients in the intervention group approximately 5 hours after bronchoscopy.
  • In this study, they showed that Unyvero has a higher sensitivity than conventional microbiological culture when clinical syndrome or imaging is used as the reference standard.
  • OpGen, Inc.(Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.
  • This press release includes statements regarding the publication of results of a recent clinical study of the Unyvero Hospitalized Pneumonia panel.

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Retrieved on: 
Thursday, May 26, 2022
Lists of diseases, DNA, Babraham Institute, Genome, Company, Disease, Research, Coronary heart disease, susceptibility to, 8, Multiomics, Challenge, Science, VC, Patient, Solution, Health, UK Research and Innovation, Thane, Institute, BBSRC, Neurodegeneration, Mentorship, Industry, Genetic code, Life, Genomics, Biomarker, Technology, Biotechnology, Biotechnology and Biological Sciences Research Council, Maintenance, Precision medicine, Biology, 3D, Family, Innovation, Pharmaceutical industry, Antibiotics, Financial services, Medical imaging, EU

CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .

Key Points: 
  • CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .
  • Debora Lucarelli, Chief Executive Officer of Enhanc3D Genomics, commented: "Our vision is to leverage the human 3D genome and state-of-the-art analytics of our platform GenLink3DTMto enable breakthroughs in precision medicine.
  • We invested in Enhanc3D with a strong belief that GenLink3DTM will revolutionise patient centric medicine as a first-in-class 3D genomics navigator.
  • ENHANC3D GENOMICS ("Enhanc3D") is a private functional genomics company based in Cambridge, UK which was founded in 2020 out of Professor Peter Fraser's pioneering 3D genome organisation research laboratory at the Babraham Institute.

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Retrieved on: 
Thursday, May 26, 2022
Lists of diseases, DNA, Babraham Institute, Genome, Company, Disease, Research, Coronary heart disease, susceptibility to, 8, Multiomics, Challenge, Science, VC, Patient, Solution, Health, UK Research and Innovation, Thane, Institute, BBSRC, Neurodegeneration, Mentorship, Industry, Genetic code, Life, Genomics, Biomarker, Technology, Biotechnology, Biotechnology and Biological Sciences Research Council, Maintenance, Precision medicine, Biology, 3D, Family, Innovation, Pharmaceutical industry, Antibiotics, Financial services, Medical imaging, EU

CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .

Key Points: 
  • CAMBRIDGE, England, May 26, 2022 /PRNewswire/ -- ENHANC3D GENOMICS ("Enhanc3D"), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation's Immunology Innovations QuickFire Challenge .
  • Debora Lucarelli, Chief Executive Officer of Enhanc3D Genomics, commented: "Our vision is to leverage the human 3D genome and state-of-the-art analytics of our platform GenLink3DTMto enable breakthroughs in precision medicine.
  • We invested in Enhanc3D with a strong belief that GenLink3DTM will revolutionise patient centric medicine as a first-in-class 3D genomics navigator.
  • ENHANC3D GENOMICS ("Enhanc3D") is a private functional genomics company based in Cambridge, UK which was founded in 2020 out of Professor Peter Fraser's pioneering 3D genome organisation research laboratory at the Babraham Institute.

Exscientia Business Update for First Quarter 2022

Retrieved on: 
Wednesday, May 25, 2022
Research, Technology, FDA, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Cancer, ID, Company, BMS, International, Medicine, Federal Reserve Bank of New York, Deep learning, ALK, Multimedia, Patient, AACR, American Association for Cancer Research, Phenomics, BST, Association, A2A, Adenosine, University, Bristol Myers Squibb, Centaur, Research, IND, CDK7, Probability, Toxicity, CTA, Biomarker, Table, Federal Reserve Bank, American Association, Precision medicine, Drug discovery, Video game, Medical device, Medical imaging, Online gambling, Pharmaceutical industry, Sanofi

View the full release here: https://www.businesswire.com/news/home/20220525005906/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220525005906/en/
    Recent advancements in the Companys pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below.
  • In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m.
  • "We are well-capitalised and are continuing to build an organisation with a balanced business model.
  • A replay will be available for 90 days under "Events and Presentations in the Investors and Media section of the Exscientia website .

Cancer Care Is Different Coalition Applauds California Senate on Passage of Landmark Cancer Care Access Legislation

Retrieved on: 
Wednesday, May 25, 2022
Oncology, Public Policy, Government, Health, State, Local, Public Policy, Other Policy Issues, Breast, Colon, Risk, Death, Timeline of Richard Branson's business ventures, Advocacy, Disease, African Americans, Hispanic, Assembly, Breast cancer, Incidence, Patient, Woman, Insurance, California Senate Constitutional Amendment No. 5, California State Senate, 987, Legislation, CCID, City, Leukemia & Lymphoma Society, 2009 Davis Cup, Medi-Cal, Public policy, University of California, Davis, Life, Prostate cancer, Man, University, Leukemia, Lung, Joe Biden, Precision medicine, Senate, Oncology, Cancer Breakthroughs 2020, Cancer, Diagnosis, Health insurance, Pharmaceutical industry, Medical imaging

The Cancer Care Is Different (CCID) Coalition today celebrates the unanimous California State Senate passage of the California Cancer Care Equity Act (SB 987) , a bill that would expand access to specialized cancer care for Medi-Cal patients diagnosed with complex cancers.

Key Points: 
  • The Cancer Care Is Different (CCID) Coalition today celebrates the unanimous California State Senate passage of the California Cancer Care Equity Act (SB 987) , a bill that would expand access to specialized cancer care for Medi-Cal patients diagnosed with complex cancers.
  • If passed, the California Cancer Care Equity Act (CCCEA) would help remove barriers that prevent access to leading-edge care for Medi-Cal beneficiaries a group who represents approximately one-third of Californias population .
  • The California Cancer Care Equity Act, if passed, will be a major milestone in improving access to care and reducing disparities in cancer outcomes.
  • We applaud the California Senate for advancing the California Cancer Care Equity Act, a crucial step toward expanding access to care for underserved patients in California, said Molly Guthrie, vice president of Public Policy & Advocacy for Susan G. Komen.

Transgene’s Combined General Meeting of May 25, 2022

Retrieved on: 
Wednesday, May 25, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Research, Claude Bernard University Lyon 1, European Society for Medical Oncology, University, SPH, Artificial intelligence, Risk, AstraZeneca, Oncology, Novartis, Medical Affairs Bureau, Immunotherapy, European Commission, Kite Pharma, List of life sciences, Therapy, Marketing, Institute, Vaccination, Century, EVP, Acquisition, Growth, Potyvirus, University of Milan, MDL, Doctor of Philosophy, AMF, Director general, National academy, Adult, TNG, Hematology, Corporate law, ESMO, Cell, European Organization for Quality, Transgene, Ernst & Young, Board, Law, Patient, Treatment, Ernst, NEC, National Cancer Institute, Forward-looking statement, European Commission–AstraZeneca COVID-19 vaccine dispute, Precision medicine, Gilead Sciences, CEO, Pharmaceutical industry, Vaccine, Cancer, Axicabtagene ciloleucel, Euronext, EU

Detailed voting results are available on Transgenes website, under the heading Investors > General Meeting.

Key Points: 
  • Detailed voting results are available on Transgenes website, under the heading Investors > General Meeting.
  • Prior to Gilead, Dr. Riva was EVP, Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals.
  • Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Lon Brard Center in Lyon since 2014.
  • With Transgenes myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual.